Revolution Medicines (NASDAQ: RVMD) just landed one of the biggest wins in oncology this year, and the stock barely blinked. On Aug. 26, the FDA approved RASONQUE (daraxonrasib), the first broad RAS-targeted therapy for metastatic pancreatic cancer.
In the pivotal RASolute 302 trial, patients on RASONQUE nearly doubled their median overall survival compared to standard chemotherapy.